TY - JOUR
T1 - Long-term survival with IDH wildtype glioblastoma
T2 - first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
AU - Hertler, Caroline
AU - Felsberg, J. rg
AU - Gramatzki, Dorothee
AU - le Rhun, Emilie
AU - Clarke, Jennifer
AU - Soffietti, Riccardo
AU - Wick, Wolfgang
AU - Chinot, Olivier
AU - Ducray, François
AU - Roth, Patrick
AU - McDonald, Kerrie
AU - Hau, Peter
AU - Hottinger, Andreas F.
AU - Reijneveld, Jaap
AU - Schnell, Oliver
AU - Marosi, Christine
AU - Glantz, Michael
AU - Darlix, Amélie
AU - Lombardi, Giuseppe
AU - Krex, Dietmar
AU - Glas, Martin
AU - Reardon, David A.
AU - van den Bent, Martin
AU - Lefranc, Florence
AU - Herrlinger, Ulrich
AU - Razis, Evangelia
AU - Carpentier, Antoine F.
AU - Phillips, Samuel
AU - Rudà, Roberta
AU - Wick, Antje
AU - Tabouret, Emeline
AU - Meyronet, David
AU - Maurage, Claude-Alain
AU - Rushing, Elisabeth
AU - Rapkins, Robert
AU - Bumes, Elisabeth
AU - Hegi, Monika
AU - Weyerbrock, Astrid
AU - Aregawi, Dawit
AU - Gonzalez-Gomez, Christian
AU - Pellerino, Alessia
AU - Klein, Martin
AU - Preusser, Matthias
AU - Bendszus, Martin
AU - Golfinopoulos, Vassilis
AU - von Deimling, Andreas
AU - Gorlia, Thierry
AU - Wen, Patrick Y.
AU - Reifenberger, Guido
AU - Weller, Michael
N1 - Funding Information: This work was supported by a generous grant from the Brain Tumor Funders’ Collaborative ( American Brain Tumor Association , Brain Tumour Foundation of Canada , James S. McDonnell Foundation , Children’s Brain Tumor Foundation , The Sontag Foundation ) and by the EORTC Brain Tumor Group . Funding Information: The authors acknowledge a generous starting grant from the Brain Tumor Funders’ Collaborative that made this project possible and as a donation from the University of Zurich, Switzerland, and to wish to thank all colleagues and staff at the European Organisation for Research and Treatment of Cancer (EORTC, Brussels, Belgium), at the participating sites, and finally, all patients and caregivers that supported this project (see note S1 ). Publisher Copyright: © 2023 The Authors
PY - 2023/8
Y1 - 2023/8
N2 - Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. Methods: European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. Results: At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24–78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O 6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9–11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours. Conclusions: Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Patients without relapse often have MGMT promoter-unmethylated glioblastoma and may represent a distinct subtype of glioblastoma.
AB - Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. Methods: European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. Results: At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24–78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O 6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9–11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours. Conclusions: Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Patients without relapse often have MGMT promoter-unmethylated glioblastoma and may represent a distinct subtype of glioblastoma.
KW - IDH
KW - MGMT
KW - Outcome
KW - Prognosis
KW - Registry
KW - Wildtype
UR - http://www.scopus.com/inward/record.url?scp=85160695493&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejca.2023.05.002
DO - https://doi.org/10.1016/j.ejca.2023.05.002
M3 - Article
C2 - 37277265
SN - 0959-8049
VL - 189
JO - European Journal of Cancer
JF - European Journal of Cancer
M1 - 112913
ER -